MPM Medical Expands U.S. Manufacturing Capabilities, Acquires FDA 510(k) for Surgical and Advanced Wound Care Collagen

New production capacity strengthens MPM Medical's position as a leading U.S. manufacturer and follows the company's recent launch of collagen at-home wound care kits

MESQUITE, Texas, Dec. 16, 2025 /PRNewswire/ -- MPM Medical today announced a major expansion of its U.S. manufacturing capabilities with the acquisition of a full collagen manufacturing platform and the associated FDA 510(k) clearance for surgical collagen devices. This expansion significantly enhances MPM Medical's ability to serve advanced wound care, surgical, and private-label partners with high-quality, American-made collagen products.

This announcement follows last week's national press release introducing MPM Medical's Collagen At-Home Wound Care Kits and Proprietary Wound Care Portal, reinforcing the company's strategy to expand both its digital and manufacturing infrastructure in support of clinicians, health systems, and patients nationwide.

Beginning January 1, 2026, the company's collagen production will operate out of MPM Medical's 100,000 sq. ft. FDA-registered facility in Mesquite, Texas. The expansion includes advanced collagen processing technology, USP-grade compounding, and several high-capacity lyophilizers—dramatically increasing output for both branded products and growing private-label demand.

Click here to read the full article.